RBM17

Across TCGA pan-cancer cohorts, RBM17 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of RBM17’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where RBM17 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RBM17 is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

HNSC, LIHC, and STAD are the cancer types where RBM17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RBM17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+0.881	<.001	12	view →
LIHC	Female	II,III,IV	+1.020	<.001	9	view →
STAD	Male	II,III,IV	+1.001	<.001	9	view →
COAD	Male	IV	+0.650	<.001	9	view →
BLCA	All	All	+0.565	<.001	9	view →
KICH	Female	All	−0.994	<.001	6	view →
CHOL	Male	All	+1.963	<.001	5	view →
LUSC	Male	II,III,IV	+0.541	<.001	5	view →
ESCA	All	All	+0.817	<.001	3	view →
THCA	Male	All	+0.254	.003	3	view →
KIRC	All	All	+0.148	.027	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

RBM17–HNSC

Open the HNSC breakdown →